Candriam S.C.A. Has $3.68 Million Stake in Kura Oncology, Inc. (NASDAQ:KURA)

Candriam S.C.A. reduced its holdings in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 53.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 422,652 shares of the company's stock after selling 483,830 shares during the period. Candriam S.C.A. owned about 0.54% of Kura Oncology worth $3,681,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Point72 DIFC Ltd acquired a new stake in shares of Kura Oncology during the 3rd quarter valued at about $146,000. Erste Asset Management GmbH acquired a new stake in shares of Kura Oncology during the 3rd quarter valued at about $215,000. Bellevue Group AG boosted its position in shares of Kura Oncology by 36.0% during the 3rd quarter. Bellevue Group AG now owns 13,600 shares of the company's stock valued at $266,000 after acquiring an additional 3,600 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Kura Oncology in the 3rd quarter valued at $268,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Kura Oncology in the 3rd quarter valued at $298,000.

Insider Activity at Kura Oncology

In other news, insider Mollie Leoni sold 4,963 shares of the firm's stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the sale, the insider now owns 88,253 shares of the company's stock, valued at $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Thomas James Doyle sold 4,949 shares of the firm's stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the sale, the senior vice president now directly owns 88,193 shares in the company, valued at approximately $694,078.91. This represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,729 shares of company stock worth $92,307 in the last ninety days. Company insiders own 5.50% of the company's stock.

Remove Ads

Analysts Set New Price Targets

A number of equities analysts have commented on KURA shares. TD Cowen reissued a "buy" rating on shares of Kura Oncology in a research note on Thursday, November 21st. BTIG Research lowered Kura Oncology from a "buy" rating to a "neutral" rating in a research note on Thursday, February 6th. JMP Securities reissued a "market outperform" rating and issued a $28.00 price objective on shares of Kura Oncology in a research note on Thursday, February 6th. Cantor Fitzgerald raised Kura Oncology to a "strong-buy" rating in a research note on Tuesday, March 4th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $40.00 price objective on shares of Kura Oncology in a report on Thursday, February 27th. Three research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Kura Oncology presently has a consensus rating of "Moderate Buy" and an average price target of $25.50.

Kura Oncology Trading Down 3.4 %

NASDAQ KURA traded down $0.26 during trading hours on Monday, hitting $7.28. The company's stock had a trading volume of 715,760 shares, compared to its average volume of 1,571,593. The stock has a fifty day moving average of $8.00 and a 200 day moving average of $13.29. Kura Oncology, Inc. has a twelve month low of $6.98 and a twelve month high of $24.17. The firm has a market capitalization of $587.49 million, a P/E ratio of -3.10 and a beta of 0.85. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.65) by $0.43. The firm had revenue of $53.88 million during the quarter, compared to analyst estimates of $57.96 million. Equities research analysts forecast that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.